Osaka University YAP-CTGF Axis Breakthrough: Preventing Liver Fibrosis, Portal Hypertension, and Cancer

Breakthrough Discovery from Osaka University Illuminates Path to Liver Health

Researchers at Osaka University have unveiled a groundbreaking molecular pathway that could transform the management of chronic liver conditions. Published on February 27, 2026, in the prestigious journal Gastroenterology, the study identifies the integrin αV-YAP-CTGF axis in liver sinusoidal endothelial cells (LSECs) as a critical driver of liver fibrogenesis in congestive hepatopathy (CH). This finding holds immense promise for preventing progression to severe complications like fibrosis, portal hypertension, and liver cancer.

Liver sinusoidal endothelial cells, often abbreviated as LSECs, line the tiny blood vessels within the liver known as sinusoids. These fenestrated cells play a vital role in regulating blood flow, nutrient exchange, and immune surveillance. In chronic liver congestion, where blood backs up due to heart failure or other circulatory issues, LSECs face elevated hydrostatic pressure, triggering a cascade of pathological changes.

Understanding Congestive Hepatopathy: A Growing Concern in Japan

Congestive hepatopathy arises from sustained hepatic venous outflow obstruction, commonly seen in conditions like right heart failure, Fontan-associated liver disease (FALD), or Budd-Chiari syndrome. Unlike inflammatory liver injuries from viruses or alcohol, CH is primarily pressure-driven, leading to sinusoidal dilation, capillarization of LSECs, and eventual fibrosis without prominent inflammation.

In Japan, where cardiovascular diseases are prevalent and Fontan procedures for congenital heart defects have increased, CH represents a significant clinical challenge. Globally, liver diseases claim two million lives annually, with fibrosis and cirrhosis as key precursors to hepatocellular carcinoma (HCC). Japan reports around 1.5 million hepatitis C carriers historically, but non-viral causes like metabolic dysfunction-associated steatotic liver disease (MASLD) are rising, amplifying fibrosis risks.

This Osaka University study addresses a gap by pinpointing how mechanical stress in CH initiates fibrosis specifically through LSEC dysfunction.

The Integrin αV-YAP-CTGF Axis: Step-by-Step Mechanism

The research meticulously delineates the pathway: Elevated hydrostatic pressure in pericentral LSECs activates integrin αV, a mechanosensor transmembrane receptor. This triggers nuclear translocation of Yes-associated protein (YAP), a transcriptional co-activator in the Hippo signaling pathway that promotes proliferation and anti-apoptosis.

• Step 1: Hydrostatic pressure binds/stresses integrin αV on LSEC surface.
• Step 2: Integrin signaling stabilizes YAP, enabling its entry into the nucleus.
• Step 3: Nuclear YAP induces connective tissue growth factor (CTGF) expression, the most upregulated gene in pericentral LSECs per single-cell RNA sequencing (scRNA-seq).
• Step 4: LSEC-derived CTGF binds back to integrin αV on LSECs (positive feedback) and activates hepatic stellate cells (HSCs), upregulating type I collagen (COL1) for extracellular matrix deposition and type IV collagen (COL4) for basement membrane formation.
• Step 5: Resulting capillarization (loss of fenestrae), fibrosis, elevated portal pressure, and HCC promotion.

This feedback loop was confirmed via coculture experiments and pressure stimulation models.

Experimental Models: From Mice to Human Relevance

Lead author Seiya Kato and senior author Hayato Hikita employed partial inferior vena cava ligation (pIVCL) in mice to mimic CH, inducing pressure without inflammation. scRNA-seq on post-pIVCL livers highlighted integrin/YAP activation and CTGF surge in LSECs. Endothelial-specific CTGF knockout (Ctgf^iΔEC) dramatically reduced fibrosis (Sirius red staining, hydroxyproline levels), portal hypertension, and tumor burden at 48 weeks.

Integrin αV inhibitor CWHM-12 administration post-pIVCL suppressed the axis, alleviating pathology. Human livers from 15 Fontan patients showed YAP/CTGF upregulation in dilated sinusoids via immunohistochemistry and spatial transcriptomics, correlating with fibrosis stage.

Therapeutic Horizons: Targeting the Axis for Prevention

"This newly identified pathway could offer a new direction for treatment," notes Hayato Hikita. Integrin αV inhibitors, already in clinical trials for other fibroses, show tolerability. LSEC-targeted delivery via lipid nanoparticles could enhance specificity. CTGF as a biomarker tracks progression, while YAP modulators (e.g., verteporfin) warrant exploration.

For Japan's aging population, where HCC incidence remains high despite viral declines, this offers proactive intervention post-Fontan or in heart failure cohorts.

Osaka University's Legacy in Gastroenterology Research

Osaka University's Graduate School of Medicine, Department of Gastroenterology and Hepatology, excels in liver research, from NASH biomarkers to HCC models. Led by figures like Tetsuo Takehara, the team leverages advanced genomics and animal models. This YAP-CTGF work builds on prior Hippo pathway studies in liver cancer.

The university's Integrated Frontier Research for Medical Science Division supports transdisciplinary efforts, fostering innovations like this.

Japan's Liver Disease Landscape and Research Momentum

Japan leads Asia in cirrhosis management, with HCV eradication reducing viral HCC, but MASLD now affects ~30% globally, mirroring trends here. Portal hypertension complicates 16-63% of advanced fibrosis cases. National initiatives like AMED funding bolster such discoveries.

Collaborations with RIKEN and others position Osaka U as a hub for mechanobiology in hepatology.

Stakeholder Perspectives: Clinicians, Patients, and Industry

Fontan patients, numbering thousands in Japan, face 2-5% annual fibrosis risk. Cardiologists and hepatologists hail this as a bridge between heart-liver axes. Industry eyes αV inhibitors for repurposing.

Future Outlook: From Bench to Bedside

Prospective trials validating CTGF as biomarker and testing inhibitors in FALD are next. Precision medicine tailoring interventions by LSEC profiling could personalize care. Long-term, disrupting this axis may halve fibrosis progression, curbing Japan's HCC burden.

Photo by Nelemson Guevarra on Unsplash

Careers in Hepatology: Join Japan's Research Frontier

This study underscores demand for experts in liver mechanobiology. Explore research jobs or university positions at institutions like Osaka U. Aspiring professors can find professor jobs in gastroenterology. For career advice, visit higher-ed career advice.

Rate inspiring mentors at Rate My Professor and browse Japan higher ed jobs.